Department of Error (DOI:10.1016/S0140-6736(08)61815-2);Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

The Lancet

Volumn 373, Issue 9660, 2009, Pages 301-308

  Widmark, Anders ^a   Klepp, Olbjørn ^b   Solberg, Arne ^c   Damber, Jan Erik ^d   Angelsen, Anders ^c   Fransson, Per ^a   Lund, Jo Åsmund ^c   Tasdemir, Ilker ^e   Hoyer, Morten ^f   Wiklund, Fredrik ^g   Fosså, Sophie D ^h  

^a UMEÅ UNIVERSITY   (Sweden)

^b lesund Hospital   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g KAROLINSKA INSTITUTE   (Sweden)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; PROCREN DEPOT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCRINE FUNCTION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORWAY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SWEDEN; UNSPECIFIED SIDE EFFECT;

EID: 58649103315     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60686-3     Document Type: Erratum

References (34)

1. Boustead G., and Edwards S.J. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. Br J Urol Int 99 (2007) 1383-1389
2. Granfors T., Modig H., Damber J.E., and Tomic R. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176 (2006) 544-547
3. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 2497-2504
4. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
5. D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., and Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008) 289-295
6. Lawton C.A., DeSilvio M., Roach M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
7. Iversen P., Johansson J.-E., Lodding P., et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7·1 years. Scand J Urol Nephrol 40 (2006) 441-452
8. McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., and Wirth M.P. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247-254
9. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51 (1998) 389-396
10. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6·3 years of followup. J Urol 164 (2000) 1579-1582
11. Boccon-Gibod L., Fournier G., Bottet P., et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32 (1997) 391-395
12. Seidenfeld J., Samson D.J., Hasselblad V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132 (2000) 566-577
13. Widmark A., Fosså S.D., Lundmo P., et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 61 (2003) 145-151
14. Iversen P., Tammela T.L., Vaage S., et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study Number 6. Eur Urol 42 (2002) 204-211
15. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
16. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
17. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data. 2nd edn. (2002), Wiley, Hoboken, NJ, USA
18. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
19. Gray R.J. Cmprsk Package serial on line] (2001), Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston. http://biowww.dfci.harvard.edu (accessed June 2001).
20. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
21. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
22. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
23. D'Amico A.V., Renshaw A.A., Loffredo B., and Chen M.H. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110 (2007) 1723-1728
24. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.H., and Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
25. Roach M. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?. J Clin Oncol 25 (2007) 5325-5326
26. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
27. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
28. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
29. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 92 (2005) 1233-1239
30. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90 (2002) 561-566
31. Bill-Axelson A., Holmberg L., Filén F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144-1154
32. Fransson P., Damber J.E., Tomic R., Modig H., Nyberg G., and Widmark A. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 92 (2001) 3111-3119
33. Mavroidis P., al-Abany M., Helgason A.R., et al. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol 181 (2005) 293-306
34. Pirl W.F., Greer J.A., Goode M., and Smith M.R. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology 17 (2008) 148-153